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Abstract
Background: We have previously found that TLR4-deficient (TLR4-/-) mice demonstrate decreased expression of 
mucosal PGE 2 and are protected against colitis-associated neoplasia. However, it is still unclear whether PGE 2 is the 
central factor downstream of TLR4 signaling that promotes intestinal tumorigenesis. To further elucidate critical 
downstream pathways involving TLR4-mediated intestinal tumorigenesis, we examined the effects of exogenously 
administered PGE 2 in TLR4-/- mice to see if PGE 2 bypasses the protection from colitis-associated tumorigenesis.
Method: Mouse colitis-associated neoplasia was induced by azoxymethane (AOM) injection followed by two cycles of 
dextran sodium sulfate (DSS) treatment. Two different doses of PGE 2 (high dose group, 200 μg, n = 8; and low dose 
group, 100 μg, n = 6) were administered daily during recovery period of colitis by gavage feeding. Another group was 
given PGE 2 during DSS treatment (200 μg, n = 5). Inflammation and dysplasia were assessed histologically. Mucosal 
Cox-2 and amphiregulin (AR) expression, prostanoid synthesis, and EGFR activation were analyzed.
Results: In control mice treated with PBS, the average number of tumors was greater in WT mice (n = 13) than in TLR4-
/- mice (n = 7). High dose but not low dose PGE 2 treatment caused an increase in epithelial proliferation. 28.6% of PBS-
treated TLR4-/- mice developed dysplasia (tumors/animal: 0.4 ± 0.2). By contrast, 75.0% (tumors/animal: 1.5 ± 1.2, P < 
0.05) of the high dose group and 33.3% (tumors/animal: 0.3 ± 0.5) of the low dose group developed dysplasia in TLR4-/
- mice. Tumor size was also increased by high dose PGE 2 treatment. Endogenous prostanoid synthesis was 
differentially affected by PGE 2 treatment during acute and recovery phases of colitis. Exogenous administration of PGE 
2 increased colitis-associated tumorigenesis but this only occurred during the recovery phase. Lastly, PGE 2 treatment 
increased mucosal expression of AR and Cox-2, thus inducing EGFR activation and forming a positive feedback 
mechanism to amplify mucosal Cox-2.
Conclusions: These results highlight the importance of PGE 2 as a central downstream molecule involving TLR4-
mediated intestinal tumorigenesis.
Background
Patients with ulcerative colitis (UC) are at increased risk
of developing colorectal cancer. Epidemiological data has
shown that the incidence and the onset of colorectal can-
cer in patients with UC is 4 to 10 times greater and 20
years earlier than that for the normal population [1,2].
The colorectal cancer development in UC patients is spe-
cifically identified as colitis-associated cancer (CAC).
The increased incidence of colorectal cancer in patients
with UC highlights the well-known link between chronic
inflammation and carcinogenesis [3]. However, the pre-
cise mechanism linking inflammation and cancer is
unknown. Therefore, understanding the mechanisms
underlying inflammation-induced colorectal cancer will
aid in establishing new strategies for prevention and/or
treatment of CAC.
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Previous studies have shown that key mediators of
intestinal inflammation in patients with UC are arachi-
donic acid metabolites, i.e. eicosanoids [4-6]. Among the
eicosanoids, prostaglandin E 2 (PGE 2) is unique due to its
multiple roles in controlling excessive inflammation and
induction of mucosal cytoprotection [7-10]. A major
action of PGE 2 in the intestinal mucosa is induction of
epithelial proliferation in response to mucosal damage
[11]. On the other hand, PGE 2 has been implicated in the
development of colorectal cancer which results from sus-
tained over-expression of cyclooxygenase 2 (Cox-2)
[12,13]. Supporting the role of Cox-2 in intestinal cancer
development, several epidemiological studies have dem-
onstrated that long-term use of nonsteroidal anti-inflam-
matory drugs (NSAID), which are strong cyclooxygenase
inhibitors, reduces the risk of developing colorectal can-
cer [14,15]. There are many possible pathways by which
PGE 2 mediates colorectal carcinogenesis [16-18]. One of
the main pathways involving PGE 2 mediated colorectal
carcinogenesis is thought to involve epidermal growth
factor receptor (EGFR) signaling [19]. PGE 2 may induce
EGFR phosphorylation through induction of EGFR
ligands, or through intracellular mediators such as cAMP
or PI 3 kinase [20]. Increased EGFR tyrosine phosphory-
lation in the rectal mucosa of patients with UC has been
reported [21]. Since expression of both Cox-2 and PGE 2
is increased in the intestinal mucosa of patients with UC,
as well as in CAC, Cox-2 induced PGE 2 may be a causal
player in complex pathways linking chronic inflammation
to the development of CAC [22-26].
We have previously shown that TLR4-mediated signal-
ing is responsible for mucosal Cox-2 expression and PGE
2 synthesis in the setting of intestinal inflammation [27].
We have also reported that this TLR4-Cox-2-PGE 2 axis is
significantly involved in the development of intestinal
neoplasms in a murine model of CAC [28]. However, we
do not know the identity of the critical downstream mod-
ulators of TLR4. For example, we have shown that Cox-2
expression is dependent on TLR4 and that, in the absence
of TLR4, levels of PGE 2 are greatly reduced. But we do
not know if PGE 2 production is necessary and sufficient
to promote tumorigenesis in the absence of TLR4. In this
study, we sought to better understand the role of PGE 2 in
TLR4-mediated colitis-associated intestinal tumorigenesis.
We have shown that TLR4 deficient mice are protected
against the development of tumors in the CAC model
[28]. We first hypothesized that administration of PGE 2
would bypass the protection from development of intesti-
nal tumors seen in TLR4-/- mice. TLR4-/- mice treated
with high dose PGE 2 had increased size and number of
tumors compared with control TLR4-/- mice. The inci-
dence of neoplasia in PGE 2 treated TLR4-deficient mice
was similar to that of WT mice without PGE 2 treatment.
PGE  2 had an effect on the development of neoplasia
when administered during the recovery phase of colitis
but not during active colitis. Altered balance of cell-pro-
liferative PGE 2 and other endogenous anti-inflammatory
prostanoids was suspected as the mechanism for the dis-
tinct effects of PGE 2 during recovery and the acute phase
of colitis. Mice treated with PGE 2 had increased expres-
sion of Cox-2 and the EGFR-ligand, AR, leading to
increased phosphorylation and activation of EGFR, indi-
cating positive feedback. In addition, epithelial cell prolif-
eration in PGE 2-treated TLR4-/- mice was increased in a
dose-dependent manner. Our results highlight the
important role of PGE 2 in TLR4-mediated colorectal
tumorigenesis in the setting of chronic inflammation.
The TLR4-Cox-2-PGE 2 axis may be a potential target for
the establishment of more effective treatment and pre-
vention of CAC.
Methods
Animal model of colitis-associated neoplasia and 
treatments
TLR4-/- mice were purchased from Oriental Bio Service,
Inc. (Kyoto, Japan), and backcrossed to C57Bl/6J mice
(Jackson Laboratory, Bar Harbor, Maine) over 8 genera-
tions. Mice were kept in specific-pathogen free (SPF)
conditions and fed by free access to a standard diet and
water. All experiments were done according to Mount
Sinai School of Medicine and University of Miami Miller
School of Medicine animal experimental ethics commit-
tee guidelines and the experimental protocol has been
approved by Institutional Animal Care and Use Commit-
tee (IACUC).
Mouse colitis-associated neoplasia was induced as pre-
viously described [28,29]. Briefly, six to ten week old gen-
der-matched mice were injected with 7.4 mg/kg of AOM
(Sigma-Aldrich, St. Louis, MO) intraperitoneally (i.p.) at
the beginning of the experiment (day 0). Two weeks after
AOM injection, mice were given two cycles of DSS treat-
ment (Figure 1). For each cycle, 2.5% DSS (MW 36-50
kDa: ICN, Aurora, Ohio) was given in their drinking
water for 7 days followed by 14 days of recovery in which
they received normal water. PGE 2 (Cayman Chemical,
Ann Arbor, MI) was diluted in ethanol (10 mg/ml) then
further diluted in PBS. Two different doses of PGE 2 (high
dose group, 200 μg/150 μl/mouse, n = 8 and low dose
group, 100 μg/150 μl/mouse, n = 6) were administered
daily by gavage feeding during each recovery period.
Another group of mice received high dose PGE 2 (200 μg/
150 μl/mouse, n = 5) during DSS treatment (Figure 1).
The PGE 2 doses were determined by our previous study
[27]. WT mice were treated with only AOM and DSS.Hernandez et al. BMC Gastroenterology 2010, 10:82
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Body weights, stool consistency, and stool occult blood
were monitored to analyze disease activity index (DAI)
during DSS treatment and recovery phase, as described
previously [28,30]. Control mice were given PBS with eth-
anol.
Mice were sacrificed on day 56. Colons were removed,
opened longitudinally, prepared using the Swiss roll
method, fixed in 10% buffered formalin, and embedded in
paraffin [31]. Every 30 sections (5 μm) of serial cuts were
stained with hematoxylin and eosin. Histological assess-
ment was performed by a gastrointestinal pathologist
(R.X) who was blind as to the mouse genotype and treat-
ment. Severity of mucosal inflammation was graded
using a standard scoring system [28,30]. Dysplastic
lesions were determined by previously established crite-
ria [32]. The number, size, and percentage of the mucosal
surface area containing dysplasia were determined under
the microscope. The size of the lesions was calculated
using a scale micrometer on the microscope.
Cell proliferation
Colonic tissue sections were examined for cell prolifera-
tion by bromodeoxyuridine (BrdU) labeling as described
previously [28]. Mice were intraperitoneally injected with
120 mg/kg of BrdU (Sigma-Aldrich, St. Louis, MO) 90
minutes prior to sacrificing and colonic tissues were
stained using a BrdU staining kit (Zymed Laboratories
Inc, San Francisco, CA). The number of BrdU-positive
cells per well-oriented crypt were calculated in every 10
crypts for each colon segment at high magnification
under light microscopy.
TUNEL Assay
Apoptotic cells in colonic epithelial cells were detected
using the terminal deoxynucleotidyl transferase (TdT)-
mediated free 3'-OH end labeling (TUNEL) assay
(ApopTaq In Situ Apoptosis Detection Kit; Chemicon,
Temecula, CA), following the manufacturer's instruc-
tions. Sections were counterstained with 4',6-diamidino-
Figure 1 Experimental protocol. PGE 2 was administered in two different doses (high dose group 200 μg/mouse, and low dose group 100 μg/
mouse) and phases (recovery period and during DSS treatment). Control mice were given the same volume of PBS. AOM and DSS (2.5%) were admin-
istered as shown. Mice were sacrificed on day 56.Hernandez et al. BMC Gastroenterology 2010, 10:82
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2-phenylindole (DAPI). The apoptotic cells were counted
as we described previously and the ratio of TUNEL posi-
tive nuclei to 100 total nuclei in the epithelial cells
counted was calculated [27].
Cell lines and reagents
Mouse macrophage cell line RAW264.7 cells (1 × 10 6
cells/well) (ATCC, Manassas, VA) were maintained in
Dulbecco's modified Eagle's medium supplemented with
1% heat-inactivated FBS, 2 mM L-glutamine, 1% penicil-
lin/streptomycin and were incubated in 6-well plates
overnight at 37°C in a 5% CO 2 humidified incubator.
Cells were incubated with 10 μM PGE 2 (Cayman Chemi-
cal, Ann Arbor, MI) for 18 hours.
Real Time PCR
One μg of total RNA was isolated from non-tumor
colonic tissues using RNA Bee (Tel-Test, Inc., Friend-
wood, TX) and used as the template for single strand
cDNA synthesis utilizing the Transcriptor First Strand
cDNA Synthesis Kit (Roche, Indianapolis, IN) according
to the manufacturer's instructions. Quantitative real-time
PCR was performed for AR, Cox-2, MIP-2, and β-actin.
The primers and probes used in this study are as follows;
for mouse amphiregulin: sense primer, TGT CAC TAT
CTT TGT CTC TGC CAT, anti-sense primer, AGC CTC
CTT CTT TCT TCT GTT TCT; for mouse Cox-2: sense
primer, AAG GAA CTC AGC ACT GCA TCC, anti-
sense primer, ACA GGG ATT GGA ACA GCA AGG A;
for mouse MIP-2: sense primer, ATC CAG AGC TTG
AGT GTG ACG C, anti-sense primer, AAG GCA AAC
TTT TTG ACC GCC; for mouse β-actin: sense primer,
ATG ACC CAG ATC ATG TTT G, anti-sense primer,
TAC GAC CAG AGG CAT ACA. All primers were
designed using Beacon Designer 3.0 (Premier Biosoft
International, Palo Alto, CA). The cDNA was amplified
using SYBR Premix Ex Taq™ (Takara Bio Inc., Shiga,
Japan) with 7900 HT sequence detection system (Applied
Biosystems, Foster City, CA). The amplification results
were analyzed using SDS 2.2.1 software (Applied Biosys-
tems, Foster City, CA) and the gene of interest was nor-
malized to the corresponding β-actin results. Data were
expressed as fold induction relative to the lowest gene
product amplified.
Western Blot Analysis
Whole cell lysates were prepared from RAW264.7 cells,
peritoneal macrophages or colonic tissue samples using a
lysis buffer, M-PER Mammalian Protein Extraction
Reagent (Thermo, Waltham, MA), and a proteinase
inhibitor cocktail (Calbiochem, San Diego, CA). The
peritoneal macrophages were taken from TLR4-/- mice
by peritoneal lavage using sterile PBS. Protein concentra-
tion was determined by the Bradford method using Bio-
Rad Protein Assay with SmartSpec™ 3000 (Bio-Rad Labo-
ratories, Hercules, CA) and Biotek μQuant (Winooski,
VM). Lysates (10 to 30 μg) were subjected to 10%
NuPAGE and transferred to Immobilon-P PVDF mem-
branes (Millipore Corporation, Bedford, MA). The mem-
brane was blocked in 5% non-fat dry milk and was
immunoblotted with primary antibodies, followed by
HRP-conjugated corresponding secondary antibodies.
The membrane was exposed on an x-ray film using an
enhanced chemiluminescent substrate SuperSignal West
Dura Kit (Pierce Biotechnology, Rockford, IL). Antibod-
ies against phospho-EGFR (Tyr 1068, mAb) and EGFR
(rabbit polyclonal) were purchased from Cell Signaling
(Beverly, MA) and Millipore Corporation (Bedford, MA),
respectively. Anti-murine Cox-2 antibody (rabbit poly-
clonal) was purchased from Cayman Chemical (Ann
Arbor, MI). Corresponding secondary antibodies, anti-
goat and anti-rabbit -HRP were purchased from Jackson
ImmunoResearch Laboratories, Inc (West Grove, PA). ß-
actin (both human and mouse anti- ß-actin from Sigma-
Aldrich, St. Louis, MO) was used as an internal control
for protein loading.
Enzyme linked immunosorbent assay (ELISA)
Amphiregulin concentration from colonic tissue lysates
(not including the polypoid lesions) was measured by
ELISA (R & D Systems, Minneapolis, MN). ELISA was
performed per the manufacturer's instructions, and the
results were normalized with protein concentration to
demonstrate picograms of AR per mg of protein.
Immunofluorescent and immunohistochemical studies
Formalin-fixed paraffin-embedded sections were incu-
bated in 10% normal goat serum for 1 hr and stained with
anti-murine Cox-2 antibody (1:200, Cayman, Ann Arbor,
MI) overnight at 4°C, followed by FITC-conjugated anti-
rabbit IgG (1:200, Zymed Laboratories, South San Fran-
cisco, CA) for 1 h at room temperature. The specificity of
staining was confirmed using a rabbit isotype control
antibody instead of the primary antibody (Zymed Labo-
ratories, South San Francisco, CA) as we described previ-
ously [27].
For double immunofluorescent staining of CD68 and
Cox-2, sections were first incubated with 0.1% Trypsin
(Sigma, St. Louis, MO) CaCl 2 dissolved in 0.05 M Tris-
Hcl pH 7.6 for 15 min at 37°C. Subsequently, sections
were blocked in a 5% non-fat dry milk for 1 h and then
incubated with the rat anti-CD68 antibody (1:100,
MCA1957S, Serotec Ltd., Raleigh, NC) overnight at 4°C.
After washing in PBS, sections were incubated with
TRITC-conjugated rabbit anti-rat IgG (1:200, Sigma, St.
Louis, MO) for 1 h at room temperature. Sections were
then re-incubated with 5% non-fat dry milk followed byHernandez et al. BMC Gastroenterology 2010, 10:82
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Cox-2 staining as described above using FITC-conjugated
goat anti-rabbit IgG (1:200, Sigma, St. Louis, MO).
Prostaglandin measurement
Production of Prostaglandins PGE 2 and 15d-PGJ2 (15-
deoxy-delta12,14-prostaglandin-J2) in the tissue culture
supernatant was determined using EIA kit (Cayman, Ann
Arbor, MI) according to the manufacturer's instructions.
100 mg colonic tissue fragments were washed in cold PBS
containing penicillin, streptomycin, and fungizone (100
U/ml each). Samples were cultured for 24 hours in 12 well
flat bottom plates in serum free RPMI 1640 with pen-
strep.
Statistical analysis
Data were presented as mean (± SD). Graphical analyses,
statistical analysis, and nonlinear regression analysis of
the data were performed using Prism 2.0c (GraphPad
Software, San Diego, Calif.). Unpaired Student's t test was
used to determine statistical significance for two inde-
pendent samples. Comparison of more than three sub-
jects was performed by nonparametric ANOVA
(Kruskal-Wallis) followed by Mann-Whitney U test. P
values were considered significant when < 0.05.
Results
Oral PGE 2 supplementation promotes development of 
colitis-associated colorectal neoplasia in TLR4-/- mice
We have demonstrated that TLR4-/- mice are protected
against development of colitis-associated neoplasia in the
AOM-DSS model [28]. Since TLR4-/- mice are character-
ized by decreased expression of mucosal Cox-2 and PGE
2, we hypothesized that exogenous administration of PGE
2 would bypass the protection against colitis-associated
tumorigenesis in TLR4-/- mice [27,28]. We tried two dif-
ferent doses of PGE 2 (high dose; 200 μg/day, and low
dose; 100 μg/day) treatment during the recovery period.
The doses of PGE 2 were determined based on our previ-
ous study, which showed that 200 μg of PGE 2 was enough
to induce intestinal epithelial cell proliferation in TLR4-
deficient mice [27]. First, we examined the incidence of
dysplasia at day 56. High dose but not low dose PGE 2
treatment resulted in an increase in dysplasia incidence
in TLR4-/- mice. Compared to 28.6% of PBS-treated
TLR4-/- mice (n = 7) that develop dysplasia, 75% of the
high dose group and 33.3% of the low dose group devel-
oped dysplastic lesions. In comparison, the incidence of
dysplasia in WT mice was 92.3% (n = 13). When the
number of dysplastic lesions per mouse was examined, a
significant increase of dysplastic lesions was observed in
the high dose group (Figure 2A). However, this increase
in the number of dysplastic lesions was not found in the
low dose group.
Next we examined whether PGE 2 treatment influenced
the size of the dysplastic lesion. PGE 2  treatment
increased the size of the dysplastic lesions (Figure
2B)(Table 1). The average size of the lesions in the high
dose group was significantly greater than that in the PBS
treated controls (P < 0.05). These dysplastic lesions; how-
ever, were still smaller than the lesions in WT mice. Every
lesion in the low dose group was bigger than any lesion
found in PBS treated controls, but the difference did not
yield statistical significance (P = 0.37). These results sug-
gest that TLR4-mediated up-regulation of mucosal PGE 2
during the recovery phases of colitis may be responsible
for the development and growth of colitis-associated
neoplasia.
PGE 2 supplementation during ongoing mucosal damage 
does not influence the development of dysplasia in TLR4-/- 
mice
We have previously shown that PGE 2 supplementation
restores the defective mucosal repair of TLR4-/- mice
during acute DSS treatment [27]. When we compared
mucosal PGE 2 production between the acute phase (after
7 days of DSS treatment) and the chronic phase (day 56)
of colitic WT mice, the mice in the acute phase of colitis
had significantly higher production of mucosal PGE 2
than the mice in the chronic inflammatory phase (331.0 ±
202.2 vs., 223.8 ± 132.8 pg/mg, P  < 0.05). Therefore,
increased mucosal PGE 2 production might have different
roles during the acute and the chronic phases of colitis.
We thus examined whether exogenous administration
of PGE 2 during DSS treatment (acute phase of colitis)
also increased the incidence of colitis-associated neopla-
sia. Twenty percent of the mice treated with PGE 2 (n = 5,
200 μg/day) during DSS treatment developed dysplasia,
while 28.6% of PBS treated control mice (n = 7) had dys-
plasia. The average number of dysplastic lesions per
mouse was 0.6 ± 1.3 (0 - 3) and was not statistically differ-
ent from the number in PBS treated mice (0.5 ± 0.8; 0 - 2).
The size of the lesions was also similar between PGE 2
treated mice (0.6 ± 0.8 mm) and PBS treated controls (0.5
± 0.8 mm). These results suggest that increased mucosal
PGE 2 during the acute phase of colitis does not promote
tumorigenesis.
Exogenous PGE 2 acts differentially during the acute and 
recovery phases of colitis because of the altered balance 
with endogenous prostanoids
To address why PGE 2 did not act tumorigenic when given
during the acute phase of colitis, we first graded the
severity of the colitis. We have shown that PGE 2 amelio-
rates acute colitis in TLR4-/- mice if administered during
DSS treatment [27], but we do not know the effect of PGEHernandez et al. BMC Gastroenterology 2010, 10:82
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2 on chronic intestinal inflammation when given during
the recovery period of colitis. It is possible that PGE 2
treatment during the recovery period of colitis may dif-
ferentially affect intestinal inflammation and thus devel-
o p m e n t  o f  c o l i t i s - a s s o c i a t e d  n e o p l a s m s .  W h e n  w e
reviewed the disease activity index (DAI), all PGE 2
treated mice showed sustained increase of disease activity
during recovery phase of colitis mainly due to sustained
diarrhea and poor BW recovery (Figure 3A). This trend
was observed even in the mice that received PGE 2 during
DSS, although they had lower DAI during the acute phase
(Figure 3A). In addition, there were no significant differ-
ences in severity of colitis on day 56 between the mice
that received PGE 2 treatment of different doses and at
Figure 2 Administration of PGE 2 promotes development of colitis-associated neoplasia in TLR4-/- mice. A. Incidence of dysplasia. The number 
of dysplastic lesions was counted per mouse under the microscope. Data are expressed as mean (± SD) (*P < 0.05). B. Microscopic pictures of H & E 
staining in colon sections (Original magnification ×100, Bars indicate 200 μm).Hernandez et al. BMC Gastroenterology 2010, 10:82
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different times (P = 0.1391) (Figure 3B). Among each cat-
egory of histological scoring (Crypt damage, Neutrophil
infiltration, Edema, Ulcerations, Mononuclear cell infil-
tration, Epithelial regeneration, and distortion), no par-
ticular difference was observed. Thus, temporal
amelioration of colitis during DSS treatment by PGE 2 did
not result in reduction of chronic colitis.
To further clarify the underlying mechanism for the
distinct effect of PGE 2 between the acute and recovery
phases of colitis, we measured mucosal 15d-PGJ2 (15-
deoxy-delta12,14-prostaglandin-J2) synthesis in acute
(day 7 of DSS treatment) and recovery (14 days after 7
days DSS treatment) phases of colitis and compared the
effect of PGE 2 treatment on 15d-PGJ2 synthesis at the
different treatment times (Figure 3B, C). 15d-PGJ2 is
known as an anti-inflammatory prostaglandin which is
also induced by Cox-2 [33]. 15d-PGJ2 plays a role in the
prevention and/or resolution of inflammation mainly
through peroxisome proliferator-activated receptor
gamma activation [33]. In the acute phase, mucosal 15d-
PGJ2 synthesis in PGE 2 treated TLR4-/- mice was signifi-
cantly up-regulated and corresponded to the ameliora-
tion of colitis by PGE 2 treatment (Figure 3C left). The
level of mucosal 15d-PGJ2 was similar to 15d-PGJ2 syn-
thesis in DSS-treated WT mice (day 7, without PGE 2
treatment). In contrast, endogenous mucosal PGE 2 syn-
thesis was similar between PBS treated and PGE 2 treated
mice (Figure 3C right).
The up-regulation of 15d-PGJ2 synthesis was not seen
when PGE 2 was given during the recovery period of coli-
tis (Figure 3D left). In addition, the level of up-regulated
mucosal 15d-PGJ2 in the mice treated with PGE 2 during
DSS administration went down after the two week recov-
ery period (Figure 3D left). Although we do not see a dif-
ference in mucosal 15d-PGJ2 synthesis, endogenous
mucosal PGE 2  is significantly increased in the mice
treated with PGE 2 during recovery compared to the mice
treated with PGE 2 during acute colitis (Figure 3D right, P
< 0.001). These results indicate that there is a stimuli that
induces 15d-PGJ2 during active colitis but not during
recovery from colitis and that the ratio of PGE 2 vs. 15d-
PGJ2 (cell-proliferative vs anti-inflammatory prostaglan-
dins) is balanced only in the active phase of colitis. With-
out such stimuli to induce 15d-PGJ2 production,
intestinal mucosa cannot maintain the balance between
PGE 2 and 15d-PGJ2 during the recovery phase. In con-
trast, PGE 2 administration during recovery from colitis
enhances endogenous PGE 2. Exogenously administered
PGE  2  disturbs the balance between cell-proliferative
(PGE  2) and anti-inflammatory (15d-PGJ2) prostanoids
during the recovery phase but not during the acute phase
of colitis.
PGE 2 treatment during the recovery period of colitis dose 
dependently drives epithelial cell proliferation
Increased epithelial cell proliferation has been associated
with colorectal tumorigenesis [34]. We have demon-
strated that TLR4-/- mice have significantly reduced epi-
thelial cell proliferation following DSS injury compared to
WT mice. Therefore, we examined whether PGE 2-
induced tumor development in TLR4-/- mice was accom-
panied by increased epithelial proliferation. Proliferative
cells were labeled with BrdU and the number of BrdU
positive epithelial cells was counted (Figure 4A). Com-
pared to PBS treated control mice, the mice treated with
high dose PGE 2 had a significantly increased number of
BrdU positive epithelial cells per crypt (Figure 4B). Cor-
responding to the incidence of dysplasia, mice in the low
dose group did not show a significant increase in epithe-
lial cell proliferation compared to PBS treated controls.
We then confirmed if the balance of epithelial prolifera-
tion and apoptosis was disturbed in the intestine of those
mice by using TUNEL assay (Figure 4C). There were no
differences in epithelial apoptotic cell number in those
mice. These results indicate that increased epithelial pro-
liferation induced by high dose PGE 2 treatment was not
Table 1: Incidence and size of dysplasia
WT TLR4-/- PBS PGE 2 high dose PGE 2 low dose
(n = 13) (n = 7) (n = 8) (n = 6)
Incidence (%) 92.3 28.6 75 33.3
Tumors/animal
(range)
3.1 ± 1.1
(1 - 15)
0.4 ± 0.2
(0 - 2)
1.5 ± 1.2*
(0 - 3)
0.3 ± 0.5
(0 - 1)
Tumor size (mm)
(range)
3.3 ± 2.1
(1 - 8)
0.4 ± 0.8
(0.5 - 1)
1.8 ± 1.3*
(1 - 4)
0.8 ± 1.1
(2 - 2)
Percentage of mucosal surface with tumor
(range)
17.4% ± 13.8
(0 - 40)
1.4% ± 2.4
(0 - 5)
6.3% ± 4.4*
(0 - 10)
1.5% ± 0.4
(0 - 3)
* P < 0.05, compared to corresponding result in PBS treated control mice.Hernandez et al. BMC Gastroenterology 2010, 10:82
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accompanied by increased apoptosis. Therefore there
may be a threshold effect of PGE 2 to induce epithelial cell
proliferation.
PGE 2 induces mucosal amphiregulin (AR) expression and 
results in EGFR phosphorylation in the setting of chronic 
colitis
PGE 2 has been reported to induce AR expression, which
is involved in the growth of colon cancer cells through
epidermal growth factor receptor (EGFR) signaling [35].
We have shown the importance of AR in TLR4-mediated
colitis-associated tumorigenesis [28]. Having demon-
strated that PGE 2 administration bypasses the phenotype
of TLR4-/- mice, we predicted PGE 2 treatment might
increase mucosal AR expression. Real time PCR demon-
strated that mucosal AR expression was significantly
higher in both high dose and low dose groups compared
to PBS treated controls (Figure 5A). AR protein levels in
Figure 3 PGE 2 administration did not alter severity of chronic colitis. A. Cumulative disease activity index (DAI) score defined as body weight 
change, hemocult blood, and stool consistency. Score was measured three times per week. B. Histological score of colitis. There are no statistical dif-
ferences in severity of colitis between the mice that received different PGE 2 treatment doses and timing (n = 13 WT; n = 7 PBS group; n = 8 high dose 
PGE 2 200 μg group; and n = 6 low dose PGE 2 100 μg group; n = 5 PGE 2 200 μg during DSS treatment; NS: no significance). C. Mucosal 15d-PGJ2 (left 
panel) and endogenous PGE 2 (right panel) synthesis during acute colitis. Mice received AOM and after 14 days, DSS was given for 7 days. PGE 2 treat-
ment (200 μg/day) significantly up-regulates mucosal 15d-PGJ2 synthesis but not endogenous PGE 2 in TLR4-/- mice at day 7 of DSS colitis (n = 5 each). 
WT mice received only AOM and DSS. Data are expressed as mean (± SD) (*P < 0.05). D. 15d-PGJ2 (left panel) and endogenous PGE 2 (right panel) 
synthesis at 14 day recovery from DSS colitis. Mice were examined at the end of the first cycle of AOM-DSS treatment. There is no difference of 15d-
PGJ2 synthesis between TLR4-/- mice that received PGE 2 (200 μg/day) during DSS colitis and during the recovery from DSS colitis (n = 5 each, P = 
0.441). By contrast, significant increase of endogenous PGE 2 is shown in the mice that received PGE 2 during the recovery phase. This increase of en-
dogenous PGE 2 is not seen in the mice that received PGE 2 during DSS treatment (acute phase). Data are expressed as mean (± SD).Hernandez et al. BMC Gastroenterology 2010, 10:82
http://www.biomedcentral.com/1471-230X/10/82
Page 9 of 14
colon lysate measured by ELISA are consistent with the
mRNA levels (Figure 5A). This result led us ask whether
increased mucosal expression of AR activates EGFR, a
potential mechanism for increased epithelial prolifera-
tion. We examined mucosal EGFR activation (non-tumor
area) by Western blotting and found that mice in high
dose and low dose groups had increased mucosal EGFR
phosphorylation (Figure 5B). These data support a link
between PGE 2 and EGFR signaling in the colonic epithe-
lium through induction of EGFR ligands.
PGE 2 administration initiates a positive feedback loop by 
up-regulation of Cox-2 expression by macrophages
We next addressed whether PGE 2 administration influ-
enced mucosal Cox-2 expression. PGE 2 has been shown
to increase Cox-2 expression in colon cancer cells result-
ing in a positive feedback loop that contributes to deregu-
lated cell proliferation via EGFR activation [36-38]. In our
model, the high dose group but not the low dose group
showed increased mucosal Cox-2 expression compared
to the PBS treated controls (Figure 6A). Real time PCR
demonstrated no differences of mucosal MIP-2 mRNA
expression among these groups (PBS: 75.1 ± 85.4, Low
dose PGE 2: 79.3 ± 64.1, High dose PGE 2: 84.6 ± 56.3, P =
0.978). The discrepancy between the expression patterns
of Cox-2 and MIP-2 suggests that the enhanced Cox-2
expression observed in the mice that received high dose
PGE  2  was not likely part of a general inflammatory
change. Next we examined which cell type within the
mucosa is responsible for the increased Cox-2 expression
induced by PGE 2 treatment. Immunofluorescent detec-
tion of Cox-2 demonstrated that the main source of
mucosal Cox-2 was lamina propria cells after PGE 2 treat-
ment (Figure 6B). TLR4-/- mice treated with PBS had
very few Cox-2 positive cells in the mucosa. Consistent
with our previous data [28], those lamina propria cells
were mainly CD68 positive macrophages (Figure 6B). The
Cox-2 positivity was similar between the tumor and its
surrounding mucosa (Figure 6B).
Figure 4 High dose PGE 2 administration drives epithelial cell proliferation in the setting of chronic colitis. A. Immunohistochemical staining 
of incorporated BrdU. Cells under S-phase (proliferative) are labeled with BrdU as brown nuclei. Original magnification 200 ×, Bars indicate 100 μm. B 
Proliferative index (Number of BrdU positive cells per crypt) was counted in intestinal epithelial cells. BrdU positive cells were counted in 10 crypts of 
each colon segment per high power field (HPF) (30 crypts/mouse). The high dose group (n = 8) has significantly greater number of BrdU positive cells 
per crypt than PBS treated controls (n = 7). Data are expressed as mean (± SD) (*P < 0.05).Hernandez et al. BMC Gastroenterology 2010, 10:82
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Next we tried to confirm if PGE 2 enhances Cox-2
expression in murine macrophage cell line RAW246.7.
Western blot analysis showed that PGE 2 enhanced the
expression of Cox-2 (Figure 6C). Peritoneal macrophages
isolated from TLR4-/- mice also demonstrated the induc-
tion of Cox-2 in response to PGE 2 (Figure 6C). Thus,
enhanced Cox-2 expression from subepithelial mac-
rophages is a key player within the positive feedback loop
with PGE 2 over-synthesis and epithelial EGFR activation
in the induction of aberrant epithelial cell proliferation in
the process of colitis-associated tumorigenesis. Our
results indicate that PGE 2 can act upstream of Cox-2 to
amplify mucosal Cox-2 production via macrophages and
thereby enhances IEC proliferation especially during the
recovery phase of colitis.
Discussion and Conclusion
PGE  2 has been implicated in the pathogenesis of IBD
[39-41] as well as in colorectal cancer [42,43]. Accumulat-
ing evidence demonstrates elevated tissue PGE 2 levels in
human colorectal tumors compared to normal mucosa,
suggesting a significant role of PGE 2 in colorectal tum-
origenesis [43-45]. Since chronic inflammation may
induce PGE 2 secretion by increasing Cox-2 expression,
PGE 2 may be a link between inflammation and carcino-
genesis. We have described that TLR4 deficiency leads to
defective mucosal production of PGE 2, Cox-2 and AR
expression. TLR4-/- mice are protected against develop-
ment of colitis-associated neoplasia. But in vivo, we can
not determine which is the critical mediator of tumori-
genesis, since all of these molecules have been indepen-
dently implicated in the development of colorectal
neoplasms. Thus we questioned the role of PGE 2 in
TLR4-mediated colorectal tumorigenesis.
The current study demonstrates that oral PGE 2 supple-
mentation during the recovery period of colitis promotes
development of colitis-associated neoplasia in TLR4-/-
mice. Interestingly, the timing of PGE 2 administration is
critical: PGE 2 given during the acute inflammatory phase
does not increase susceptibility to neoplasia whereas dur-
ing the recovery phase it does. These data suggest a
threshold effect for PGE 2 and that PGE 2 in a recovery
milieu crosses the threshold to neoplasia. In the absence
of TLR4, PGE 2 is necessary and sufficient to induce
mucosal AR expression and EGFR phosphorylation even
in low doses. The fact that low dose PGE 2 induces similar
amounts of AR and EGFR phosphorylation as high dose
PGE 2 but does not have the same degree of proliferation
or tumorigenesis, suggests that high dose PGE 2 has alter-
nate effects that promote tumor formation. For example,
high dose PGE 2 induces Cox-2, which may activate addi-
tional genes. It is true that activation of EGFR and up-reg-
ulation of AR is not only involved in intestinal
tumorigenesis but is also involved in the normal mucosal
repair process. Therefore, the discrepancy in our results
between AR-induced EGFR activation in cellular prolifer-
ation and in tumor development suggests the different
roles of this process. While there may be more factors
involved in the regulation of the different roles of AR-
induced EGFR activation during colitis and colitis-associ-
ated tumorigenesis, our results demonstrate an impor-
tant mechanistic insight into TLR4-mediated colitis-
Figure 5 High dose PGE 2 may promote a positive feedback loop in EGFR signal-mediated cell proliferation by inducing Cox-2 expression. 
A. Mucosal expression of AR in TLR4-/- mice treated with PGE 2; day 56 in AOM-DSS model (Left graph: mRNA analyzed by real-time PCR, Right graph: 
protein measured by ELISA). Data are represented as mean (± SD) of relative values of expression (n = 7 PBS group, n = 8 high dose and n = 6 low dose 
groups, *P < 0.05). B. Western blot analysis of phosphorylated EGFR and EGFR in the colon. Results from three representative samples obtained from 
TLR4-/- mice under each treatment in AOM-DSS model. An equal amount of protein (25 μg/lane) was loaded per lane. The membrane was sequen-
tially probed for phospho-EGFR and EGFR.Hernandez et al. BMC Gastroenterology 2010, 10:82
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associated tumorigenesis. The source of the increased
Cox-2 in the mucosa is subepithelial macrophages.
Therefore, we conclude that excess PGE 2 may increase
mucosal Cox-2 expression from subepithelial mac-
rophages in the recovery period of colitis, forming a posi-
t i v e  f e e d b a c k  l oo p  t h a t  i n d u c e s  a be r r a n t  e p i t h e l i a l  c e l l
proliferation resulting in the development and growth of
colitis-associated neoplasms (Figure 7).
There are conflicting reports on the effect of exogenous
PGE 2 in mouse models of colorectal tumors. Exogenous
PGE 2 administration has been reported to increase the
number of polyps in APC-Min/+ mice [16,46]. Another
report demonstrated PGE 2 treatment reduced the num-
ber and size of polyps in APC-Min/+ mice even though
they showed increased epithelial proliferation [47]. In
another model of colorectal tumors induced by AOM,
PGE 2 treatment increased the number and size of col-
orectal tumors [48]. What is unique about our work is
that we used TLR4-/- mice to ask whether replacing PGE
2 increased their susceptibility to neoplasia. Our results
demonstrate that PGE 2 treatment during the recovery
period of colitis promotes epithelial proliferation and
increases the number and size of colitis-associated neo-
plasms in TLR4-/- mice. We have not seen these effects of
PGE 2 in WT mice (data not shown). Treatment of WT
mice with exogenous PGE 2 during acute colitis had no
effect on epithelial proliferation [27]. These results indi-
cate that there are distinct roles of PGE 2 in intestinal
mucosal homeostasis and tumorigenesis. The dose of
PGE  2 also changes the role of PGE 2; low dose PGE 2
Figure 6 PGE 2-mediated up-regulation of Cox-2 expression. A. Real-time PCR results for mucosal Cox-2 mRNA expression in TLR4-/- mice treated 
with PGE 2; day 56 in AOM-DSS model. Data are represented as mean (± SD) of relative values of expression (n = 7 PBS group; n = 8 high dose group, 
PGE 2 200 μg; and n = 6 low dose group, PGE 2 100 μg; n = 5 PGE 2 during DSS treatment, PGE 2 200 μg; *P < 0.05). B. Immunofluorescent staining for 
Cox-2 in the colon. Representative pictures show Cox-2 positive cells (green - FITC) in lamina propria cells. High dose PGE 2 treated mice show many 
Cox-2 positive cells in the lamina propria. Low dose PGE 2 treated mice and PBS treated mice have very few Cox-2 positive cells in lamina propria. Dou-
ble staining demonstrates most Cox-2 positive cells (green - FITC) are also positive for CD68 (red - TRITC) both in the non-tumor area (middle panel) 
and tumor area (bottom) (serial pictures in same area are shown). Original magnification: 400 ×. Bars indicate 50 μm. C. Western blot analysis of Cox-
2 production in murine macrophage cell line RAW246.7 and TLR4-/- peritoneal macrophages. Representative results from three independent exper-
iments. Cells were treated with 10 μM PGE 2 for 18 hours. An equal amount of protein was loaded per lane. The membrane was sequentially probed 
for Cox-2 and β-actin.Hernandez et al. BMC Gastroenterology 2010, 10:82
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treatment did not induce epithelial proliferation or
increase colorectal neoplasms. When we used 16,16-dim-
ethyl-PGE 2 either by i.p injection or gavage feeding (200
or 100 μg/150 μl/mouse, daily), all TLR4-/- mice suc-
cumbed during the active colitis period due to aggravated
colitis (data not shown). Although PGE 2 has been impli-
cated in intestinal cytoprotection against acute mucosal
damage, overproduction or prolonged production of PGE
2 may worsen colitis or induce tumorigenesis, respectively
[49-52]. Our results suggested that the balance of
mucosal PGE 2 level to 15d-PGJ2 is important in deter-
mining the PGE 2-mediated effect in the intestine. This
idea is further supported by the fact that different prosta-
glandin EP receptor subtypes cause different effects in
the intestinal mucosa, and individual EP receptor sub-
types are activated by different concentrations of PGE 2
[53-57]. Another aspect that merits explanation is
whether different EP receptor subtypes are induced dur-
ing different phases of inflammation. TLR4-/- mice have
defective mucosal PGE 2 synthesis and are more suscepti-
ble to DSS-induced colitis [27,58]. Therefore, TLR4-
mediated PGE 2 production is necessary for restitution
during acute inflammation but its continued production
is detrimental. This finding provides an important insight
into targeting PGE 2 during specific phases of IBD.
We have described AR and EGFR as downstream
mechanisms used by PGE 2 to enhance tumorigenesis. In
addition, PGE 2  induced mucosal Cox-2 expression
mainly in subepithelial macrophages, has been implicated
in TLR-mediated induction of epithelial cell regeneration
and proliferation through Cox-2 expression [59,60].
Induction of cAMP is the key pathway involved in PGE 2-
mediated enhancement of Cox-2 expression in mac-
rophages [36,61]. Because TLR4 potentially induces Cox-
2, this may explain why mucosal PGE 2 is not down-regu-
lated during the recovery period when active inflamma-
tion is gone. The positive feedback loop involving Cox-2,
PGE 2, AR expression, and EGFR activation is therefore
crucial in TLR4-mediated colitis-associated tumorigene-
sis.
Selective Cox-2 inhibitors are available for clinical use
and are effective in reducing the risk of intestinal ade-
nomatous polyps, although routine use for cancer
chemoprevention remains problematic because of the
increased cardiovascular complications with long-term
use [62,63]. Studies in patients with UC in remission
demonstrated that celecoxib, a selective Cox-2 inhibitor,
did not cause the disease to flare [64]. Based on our cur-
rent study, we suggest that targeting TLR4 or PGE 2 over-
production during the quiescent phase of colitis may have
a potent beneficial effect on the prevention of CAC.
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Figure 7 Role of PGE2 in bridging TLR4 signaling and intestinal 
tumorigenesis. A. In WT intestine, TLR4 expression is increased in 
chronic inflammation and PGE 2 synthesis is induced by Cox-2 induc-
tion. Produced PGE 2 stimulates the expression and release of AR and 
then EGFR activation either directly or through AR release. Sustained 
activation of this pathway results in aberrant cell proliferation and tu-
morigenesis. B. In the absence of TLR4, chronic intestinal inflammation 
does not induce tumorigenesis. C. When PGE 2 is exogenously admin-
istered to TLR4-/- mice Ђ, PGE 2 activates EGFR either directly 4 or 
through AR 23. This may be not enough to induce tumorigenesis. 
However, exogenous PGE 2 induces Cox-2 production in macrophages 
5 that causes the release of endogenous PGE 2, forming a positive 
feedback loop, which induces tumorigenesis 6.Hernandez et al. BMC Gastroenterology 2010, 10:82
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